Regional Analysis

Global Pancreatic Cancer Therapeutics and Diagnostic Market: Regional Insights

Based on geography, the global pancreatic cancer therapeutics and diagnostic market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period owing to the increasing incidence and prevalence of pancreatic cancer and surging demand for safe, effective treatment options in the region. For instance, according to the American Cancer Society, in 2022, more than 62,210 people (32,970 men and 29,240 women) in the United States will be diagnosed with pancreatic cancer, and over 49,830 people (25,970 men and 23,860 women) will die of pancreatic cancer. Pancreatic cancer therapeutics and diagnostics is a medical procedure used to diagnose pancreatic cancer and their subsequent treatment.

Europe is also expected to witness robust growth in the global pancreatic cancer therapeutics and diagnostic market owing to the increasing burden of pancreatic cancer and increase in demand for effective therapeutics and diagnostics in the region. For instance, according to the United European Gastroenterology, number of deaths from pancreatic cancer has almost doubled in the past three decades and it now claims the lives of more than 90,000 EU (European Union) citizens every year. Moreover, pancreatic cancer is currently one of the leading cause of cancer deaths in Europe, this in turn is expected to aid in the growth of the market.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa